Donate

Industry News

Bayer Hemophilia Leadership Development Program

February 3, 2011

Apply for the Bayer Hemophilia Leadership Development Program today. It’s your chance to participate in a summer internship that will help develop the skills needed to be a successful leader. Take this opportunity to ask questions, learn from business professionals, develop key relationships, prepare for real-world transitions after college, and more importantly, have FUN! Deadline […]

Pfizer Inc. And Progenics Alert Physicians And Patients To Information Related To Triad Group Alcohol Prep Products Included In U.S. RELISTOR Kit Packaging Wed, 26 Jan 2011 10:53:00 -0600 NEW YORK, N.Y. and TARRYTOWN, N.Y.

January 26, 2011

Pfizer Inc. and Progenics Pharmaceuticals, Inc. have learned of a United States market recall of alcohol prep pads and swabs manufactured by the Triad Group. In the interest of patient safety, Pfizer and Progenics are alerting U.S. patients and physicians to Triad’s recall.

News Release BioRx Announces New Chief Financial Officer

January 10, 2011

January 10, 2011 (Cincinnati, Ohio)聽 BioRx announced it has hired Robin R. Johnson, MBA, CPA, as its new Chief Financial Officer. Johnson comes to BioRx from Vohra Health Services of Miami, Florida, the nation’s largest wound care provider, where she served as Interim Chief Financial Officer. At BioRx, Johnson’s responsibilities are to plan, implement, and […]

Important Information for the Hemophilia Community Regarding Triad Group’s Alcohol Prep Products and Bayer’s BayCuffTM and First Aid Kit

January 10, 2011

Click here to letter from Bayer January 10, 2011 Dear Bayer Customer: Bayer HealthCare Pharmaceuticals has become aware of a broad United States market recall of alcohol prep pads, swabs and swabsticks manufactured by the Triad Group and marketed under various brand names. In the interest of patient safety, Bayer wants to ensure that you […]

RECALL: Triad Group Issues a Voluntary Nationwide Recall of All Lots of Alcohol Prep Pads, Alcohol Swabs, and Alcohol Swabsticks Due to Potential Microbial Contamination

January 7, 2011

Article Link Contact: Eric Haertle, COO 262-538-2900 FOR IMMEDIATE RELEASE – January 5, 2011 – Hartland, Wisconsin, Triad Group, a manufacturer of over-the-counter products has initiated a voluntary product recall involving ALL LOTS of ALCOHOL PREP PADS, ALCOHOL SWABS, and ALCOHOL SWABSTICKS manufactured by Triad Group but which are private labeled for many accounts to […]

Biogen Idec Press Release: Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Lasting Recombinant Factor VIII Fc Fusion Protein

December 7, 2010

Click here for press release First Long-Lasting Factor VIII Candidate in Late-Stage Clinical Trial for Treatment of Hemophilia A WESTON, Mass. & STOCKHOLM, Dec 06, 2010 (BUSINESS WIRE) — Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) today announced that the first patient has been dosed with the companies’ long-lasting recombinant Factor VIII […]

CSL Behring Announces Availability of Next Generation HeliTrax庐 System for People with Hemophilia A

December 1, 2010

聽Custom software platform is first internet-enabled mobile application to interface directly with patient management systems used by hemophilia treatment centers 聽 KING OF PRUSSIA, Pa., Dec. 1, 2010 /PRNewswire/ — CSL Behring announced today the availability of the next generation HeliTrax® System as part of a specially designed software platform for Apple’s iPhone®, iPod touch®, […]

BioRx Offers Free 2010 Kids Hemophilia Calendar

November 24, 2010

Link to article November 9, 2009 (Cincinnati, Ohio) – BioRx, a specialty pharmaceutical company, announces the availability of a free 2010 calendar to the hemophilia community. The annual BioRx Kids Hemophilia Calendar features artwork from children who either have a bleeding disorder or have a sibling or parent with a bleeding disorder. To produce the […]

BioRx Offers Scholarships to Bleeding Disorders Community

November 24, 2010

Link to article September 1, 2010 (Cincinnati, Ohio) BioRx and Hemophilia of North Carolina announce the availability of four 2011 BioRx Educational Scholarships in the amount of $2,000 each to individuals with bleeding disorders. The scholarships will be awarded for the 2011-2012 school year, and the deadline for submitting applications is May 1, 2011. BioRx […]

Novo Nordisk announced the U.S. Food and Drug Administration (FDA) has approved NovoSeven庐 RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size.

September 2, 2010

Novo Nordisk announced聽on August 10聽that the U.S. Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation […]

Novo Nordisk provides a development update on two new investigational drugs for the bleeding disorders community.

August 30, 2010

The company’s ultra fastacting recombinant factor VIIa is progressing to a phase 3 trial after the successful completion of a phase 2 safety, pharmacokinetics and efficacy trial; the phase 3 trial is currently being designed.聽 A phase 3 trial for the factor XIII drug was recently been completed and showed that, compared to a historic […]

Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A

August 9, 2010

Pfizer Press Release Pfizer is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted approval for the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is an injectable recombinant factor VIII product previously approved by the FDA for both the […]

BioRx President Phil Rielly Wins Ernst & Young Entrepreneur of the Year庐 Award

July 28, 2010

(Cincinnati, Ohio)聽 July 20, 2010 – Philip Rielly, President and Co-founder of specialty pharmacy BioRx LLC, 聽has received the Ernst & Young Entrepreneur Of The Year® 2010 Award in the Healthcare category in South 聽Central Ohio and Kentucky.聽 According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs 聽who are building and leading dynamic, […]

Winners announced for 2010 BioRx Educational Scholarships

July 21, 2010

News Release聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 June 21, 2010 (Cincinnati, Ohio)聽聽 BioRx, a specialty pharmacy, and Hemophilia of North Carolina, a non-profit organization that assists and educates persons affected by bleeding disorders, announce the winners of the 2010 BioRx Educational Scholarships.聽 Each of the winners receives a $2,000 scholarship.聽 The scholarships are funded by BioRx through an educational grant, […]

Real-World Experience Confirms Low Inhibitor Rate Established in ADVATE Controlled Clinical Studies for Hemophilia Patients

July 14, 2010

Buenos Aires, Argentina, (July 13, 2010) – Baxter International Inc. (NYSE: BAX) today announced final E.U./U.S. post-authorization safety surveillance (PASS) data that support the safety and efficacy profile of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] previously documented in prospective clinical trials in a new study published in the journal Hemophilia. see more…advate_pass

BioRX Announces New National Director of Operations

June 24, 2010

Randy Broyles, RPh has joined BioRx as National Director of Operations. See more…Randy Boyles

CSL Behring Launches 2 New Programs this month for Patients & Caregivers

April 27, 2010

1. FactorPlus: This is a new free product trial program for Helixate FS. Some of the highlights of the program: Shipment of trial product directly to聽patients homes (physician can choose where product should go to i.e. HTC or patients home) Inclusion of ancillary supplies with every shipment A welcome kit with helpful resources Improved availability […]

TODAY GRIFOLS INTRODUCES MIX2VIAL FILTER TRANSFER SETS

April 27, 2010

Los Angeles, California (April 23, 2010). Grifols USA, LLC (Grifols) today announced the availability of the Mix2Vial鈩 transer set for the reconstitution and administratioon of Grifols’ coagulation therapies. TheMix2Vial鈩⒙犅犅爄s a plastic, needle-free transfer device with a built-in 15 micron filter specifically designed to be used with the Sterile Water for Injection diluent packaged with Grifols […]

A Tribute to Dr. Robert Janco

March 10, 2010

Disease Area Lead, Pfizer Hematology Trusted colleague, outstanding clinician and friend of the hemophilia community, Dr. Robert “Bob” Janco passed away on March 9 after a short but aggressive illness. Bob had a wealth of experience in the diagnosis and clinical management of adults and children with congenital bleeding disorders.聽He most recently served at Disease […]

Infusion Set Needles [Manufactured by Nipro for Exelint]: Recall

January 26, 2010

Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets Exel/Exelint “Securetouch+” Safety Huber Infusion Sets Audience: Hospital Risk Managers, Surgical Service personnel FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets and Exel/Exelint “Securetouch+” Safety Huber Infusion Sets, manufactured by Nipro Medical Corporation for Exelint International Corporation due to […]

340B Prime Vendor Program, managed by Apexus, and the Hemophilia Alliance announced today an innovative collaborative effort to assist participating federally funded hemophilia treatment centers.

January 14, 2010

IRVING, Texas/ Lansdale, Pa (January 14, 2010) – The 340B Prime Vendor Program, managed by Apexus, and聽 the Hemophilia Alliance announced today an innovative collaborative effort to assist participating federally funded hemophilia treatment centers in maximizing the benefits of 340B Drug Pricing Program and Prime Vendor Program discounts.聽 The two organizations are working together to […]

Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R …

January 13, 2010

Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R … FOXBusiness “Orphan drug exclusivity confirms Octapharma’s decision to focus exclusively on the treatment of von Willebrand patients. Wilate has a combination of two … Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R … 聽 聽 聽

Bayer is now accepting internship applications for the 2010 Bayer Hemophilia Leadership Development Program

December 22, 2009

The Bayer Hemophilia Leadership Development Program was developed with input from several members of the hemophilia community who saw a need for a program to develop future leaders in the bleeding disorders community. With their support, Bayer HealthCare Pharmaceuticals created an eight-week, paid summer internship at Bayer HealthCare’s U.S. Headquarters in Wayne, New Jersey. During […]

Octapharma USA Announces FDA Approval of wilate(R) – the First Replacement Therapy Developed Specifically for von Willebrand Dis

December 8, 2009

Octapharma USA Announces FDA Approval of wilate(R) – the First Replacement Therapy Developed Specifically for von Willebrand Disease 聽Milestone Marks Swiss Company’s Entrance into the U.S. Blood Coagulation Market HOBOKEN, N.J., Dec. 7 /PRNewswire/ — Octapharma USA today announced the U.S. Food and Drug Administration has approved wilate® for the treatment of spontaneous and trauma-induced […]

The WFH receives the largest humanitarian aid donation in its history

December 1, 2009

NEWS RELEASE: 聽聽Donation represents more than 40 million international units to the WFH 聽(Montreal, December 2, 2009): As part of its continued commitment to hemophilia care around the world, Wyeth, now a part of Pfizer, has pledged more than 聽40 million international units (IUs) of factor concentrates to the World Federation of Hemophilia (WFH). This […]

1st Person with Hemophilia Reaches Mt. Rainier Summit to Raise Money for Inner-city Youth and International Bleeding Disorder Assistance Jeff Salantai

November 10, 2009

News Release Cincinnati, Ohio (November 9, 2009) 鈥 聽 On August 5, 2009, two BioRx employees, Jeff Salantai and Eric Hill, began hiking to the summit of Mt. Rainier.聽 They successfully reached the 14,410-foot summit on August 6.聽聽 Hill says, “We hoped to reach one of the largest peaks in the U.S., and we achieved […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.